Viking Therapeutics

VKTX

Market cap $4.08B

Eli Lilly has been a growth beast, coming off an impressive year in which its revenue rose by 45%. Viking Therapeutics has an exciting GLP-1 drug in development that, if approved, could send its shares skyrocketing.

Viking Therapeutics aims to participate in the billion-dollar obesity market. The company's most advanced candidate is in a phase 3 trial.

Viking Therapeutics, Inc. (VKTX) reached $35.52 at the closing of the latest trading day, reflecting a +1.46% change compared to its last close.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $35.01, signifying a +2.19% move from its prior day's close.

SAN DIEGO, April 10, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will attend multiple upcoming investor conferences.  Details of the company's participation are as follows: Raymond James Biotech/BioPharma Conference 2026 Details: Viking management will participate in 1-on-1 meetingsConference Date: April 14, 2026Location: New York, NY Piper Sandler Spring Biopharma Symposium 2026 Details: Viking management will participate in 1-on-1 meetings Conference Date: April 16, 2026Location: Boston, MA About Viking Therapeutics, Inc. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders.

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $33.93, representing a -2.5% change from its previous close.

Defensive healthcare stocks such as Johnson & Johnson and CVS tend to outperform in recessions. Growth healthcare stocks offer higher risk and potential reward, less tied to economic cycles.

Viking Therapeutics has a shot at becoming a leader in the weight-loss market. However, the company's quest could run into significant obstacles.

The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the next transformative asset.